Back to Education Zone

Leading the conversation in
advanced breast cancer

Professor Angelo Di Leo

Head of the Sandro Pitigliani Medical Oncology Unit and Chair of the Oncology Department Hospital of Prato, Instituto Toscano Tumori, Italy

more >>>

Angelo Di Leo is currently Head of the Sandro Pitigliani Medical Oncology Unit and Chair of the Department of Oncology at the Hospital of Prato, Istituto Toscano Tumori, Italy, a position he took up in September 2003.After graduating in medicine and surgery at the University of Palermo, Italy in 1988, he received his postgraduate diploma in medical oncology from the University of Pavia, Italy in 1992, and in 1996 received his European certification in medical oncology.

Professor Di Leo trained at the National Cancer Institute in Milan, Italy, where he worked for 7 years until 1996. From 1996 to 2003, he worked at the Chemotherapy Unit of the Jules Bordet Institute in Brussels, Belgium, where in 1997 he was appointed senior staff member and medical director of the Breast European Adjuvant Studies Team.

Professor Di Leo’s main research interest is breast cancer, and he has coordinated a number of international, pivotal phase III trials in new adjuvant therapies. He is also heavily involved in the evaluation of molecular markers with potential predictive value for breast cancer.

The author of many peer-reviewed articles, Dr Di Leo has lectured extensively at national and international meetings. He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee, the Breast International Group Executive Board, and chair of the Biological Protocol Working Group (BPWG) – IBCSG. He has also served on the American Society of Clinical Oncology (ASCO) grants selection committee (2006–2009), the ASCO Education Committee (2012–2014), and the Scientific Advisory Council of the Susan G. Komen for the Cure® (2010-2016).

touchONCOLOGY – on demand

Watch internationally renowned clinical expert, Professor Angelo Di Leo, discuss key data in advanced breast cancer presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting, Chicago, USA.

Submit your question

What does the AACR 2018 data mean for regional clinical practice?

Watch our video interview series with six clinical experts from Europe and Japan.

Topic: key clinical data from AACR 2018 and their potential implications for optimizing clinical outcomes for patients with advanced breast cancer.